{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:33Z","timestamp":1791264093100,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.bpg.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T05:12:58Z","timestamp":1354165978000},"page":"381-389","source":"Crossref","is-referenced-by-count":16,"title":["Virology of hepatitis C virus infection"],"prefix":"10.1016","volume":"26","author":[{"given":"St\u00e9phane","family":"Chevaliez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2012.09.006_bib1","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1074\/jbc.M302267200","article-title":"Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate","volume":"278","author":"Barth","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpg.2012.09.006_bib2","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1128\/JVI.00941-06","article-title":"Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction","volume":"80","author":"Barth","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib3","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpg.2012.09.006_bib4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.25501","article-title":"Role of low-density lipoprotein receptor in the hepatitis C virus life cycle","volume":"55","author":"Albecka","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib5","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1073\/pnas.0402253101","article-title":"CD81 is an entry coreceptor for hepatitis C virus","volume":"101","author":"Cormier","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpg.2012.09.006_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bpg.2012.09.006_bib7","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpg.2012.09.006_bib8","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.bpg.2012.09.006_bib9","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1074\/jbc.M411600200","article-title":"High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I","volume":"280","author":"Voisset","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpg.2012.09.006_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2012.09.006_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2012.09.006_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.bpg.2012.09.006_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.bpg.2012.09.006_bib14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/JVI.73.2.1165-1174.1999","article-title":"A phylogenetically conserved stem-loop structure at the 5\u2032 border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation","volume":"73","author":"Honda","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bpg.2012.09.006_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1432-1033.1997.00047.x","article-title":"DNA helicase activity of the hepatitis C virus nonstructural protein 3","volume":"250","author":"Gwack","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bpg.2012.09.006_bib17","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1128\/JVI.70.12.8477-8484.1996","article-title":"The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3)","volume":"70","author":"Tai","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib18","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib19","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1128\/JVI.78.20.11393-11400.2004","article-title":"An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication","volume":"78","author":"Elazar","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1099\/vir.0.80768-0","article-title":"Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci","volume":"86","author":"Gretton","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-3527(04)63002-8","article-title":"Novel insights into hepatitis C virus replication and persistence","volume":"63","author":"Bartenschlager","year":"2004","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.bpg.2012.09.006_bib22","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1128\/JVI.73.12.9718-9725.1999","article-title":"Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation","volume":"73","author":"Shimoike","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/viro.2000.0252","article-title":"Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5\u2032 untranslated region of the viral genome","volume":"270","author":"Tanaka","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.bpg.2012.09.006_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bpg.2012.09.006_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/jhep.2002.34130","article-title":"Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication","volume":"36","author":"Bouvier-Alias","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/JCM.06503-11","article-title":"Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients","volume":"50","author":"Descamps","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bpg.2012.09.006_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/rmv.717","article-title":"Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?","volume":"22","author":"Hosseini-Moghaddam","year":"2012","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib28","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/JCM.01856-09","article-title":"New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification","volume":"48","author":"Park","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bpg.2012.09.006_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcv.2011.11.009","article-title":"HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis","volume":"53","author":"Mederacke","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2010.02.012","article-title":"Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients","volume":"48","author":"Miedouge","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bpg.2012.09.006_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000318878","article-title":"Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C","volume":"54","author":"Moscato","year":"2010","journal-title":"Intervirology"},{"key":"10.1016\/j.bpg.2012.09.006_bib32","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/JCM.01640-09","article-title":"Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification","volume":"48","author":"Ross","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bpg.2012.09.006_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.006_bib34","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2012.02.027","article-title":"New virologic tools for management of chronic hepatitis B and C","volume":"142","author":"Chevaliez","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.006_bib37","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.006_bib38","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(11)60069-X","article-title":"Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations","volume":"54","author":"Chevaliez","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.006_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hep.23407","article-title":"Dried blood spot for hepatitis C virus serology and molecular testing","volume":"51","author":"Tuaillon","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2009.10.003","article-title":"Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis","volume":"52","author":"Moreno","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.006_bib41","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/hep.23531","article-title":"Identifying hepatitis C virus genotype 2\/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin","volume":"51","author":"Diago","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib42","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.006_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep.23816","article-title":"Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response","volume":"52","author":"Buti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","article-title":"Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment","volume":"131","author":"Sanchez-Tapias","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.006_bib45","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.006_bib46","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60010-X","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"54","author":"Sullivan","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.09.006_bib47","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60011-1","article-title":"Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b\/ribavirin","volume":"54","author":"Zeuzem","year":"2011","journal-title":"J Hepatol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T22:40:47Z","timestamp":1745361647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691812000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1521691812000893"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.09.006","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}